# Yosuke Togashi

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 41 papers | 3,604 citations | 361413 20 h-index | 345221 36 g-index |
| 41 all docs | 41 docs citations | 41 times ranked | 4888 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Aging, cancer, and antitumor immunity. International Journal of Clinical Oncology, 2022, 27, 316-322. | 2.2 | 29 |
| 2 | HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability. Gastroenterology, 2022, 162, 799-812. | 1.3 | 28 |
| 3 | TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. , 2022, 9, e003134. | | 32 |
| 4 | Lactic acid promotes PD-1 expression in regulatory TÂcells in highly glycolytic tumor microenvironments. Cancer Cell, 2022, 40, 201-218.e9. | 16.8 | 266 |
| 5 | Programmed Death-Ligand 1â€“Rich Premetastatic Niche in Adjuvant Chemotherapy. Journal of Thoracic Oncology, 2022, 17, 10-12. | 1.1 | 2 |
| 6 | Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instabilityâ€“High Locally Advanced Rectal Cancer. Clinical Cancer Research, 2022, 28, 1136-1146. | 7.0 | 62 |
| 7 | PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted TÂcell clonotypes. Cell Reports, 2022, 38, 110331. | 6.4 | 45 |
| 8 | A variety of â€˜exhaustedâ€™ T cells in the tumor microenvironment. International Immunology, 2022, 34, 563-570. | 4.0 | 13 |
| 9 | Mechanisms of resistance to immune checkpoint inhibitors. Cancer Science, 2022, 113, 3303-3312. | 3.9 | 12 |
| 10 | Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. Cancer Research Communications, 2022, 2, 739-753. | 1.7 | 2 |
| 11 | <scp>HSP90</scp> inhibition overcomes <scp>EGFR</scp> amplificationâ€induced resistance to thirdâ€generation <scp>EGFRâ€TKIs</scp>. Thoracic Cancer, 2021, 12, 631-642. | 1.9 | 14 |
| 12 | Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens. Scientific Reports, 2021, 11, 341. | 3.3 | 17 |
| 13 | Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants. New England Journal of Medicine, 2021, 384, 42-50. | 27.0 | 40 |
| 14 | Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer. JCI Insight, 2021, 6, . | 5.0 | 17 |
| 15 | Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1. Blood Cancer Discovery, 2021, 2, 450-467. | 5.0 | 10 |
| 16 | Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. Science Immunology, 2021, 6, eabc6424. | 11.9 | 64 |
| 17 | Cancer-immunotherapy biomarkers in the tumor microenvironment. Okayama Igakkai Zasshi, 2021, 133, 151-157. | 0.0 | 0 |
| 18 | The potential application of PD-1 blockade therapy for early-stage biliary tract cancer. International Immunology, 2020, 32, 273-281. | 4.0 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). Clinical Cancer Research, 2020, 26, 5887-5894. | 7.0 | 44 |
| 20 | The critical role of CD4+ T cells in PD-1 blockade against MHC-IIâ€“expressing tumors such as classic Hodgkin lymphoma. Blood Advances, 2020, 4, 4069-4082. | 5.2 | 76 |
| 21 | The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nature Immunology, 2020, 21, 1346-1358. | 14.5 | 431 |
| 22 | Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer. Gastric Cancer, 2020, 23, 893-903. | 5.3 | 20 |
| 23 | An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. Immunity, 2020, 53, 187-203.e8. | 14.3 | 119 |
| 24 | Association between the mutational smoking signature and the immune microenvironment in lung adenocarcinoma. Lung Cancer, 2020, 147, 12-20. | 2.0 | 5 |
| 25 | Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated nonâ€“small cell lung cancer. Science Immunology, 2020, 5, . | 11.9 | 160 |
| 26 | Clinical and immune profiling for cancer of unknown primary site. , 2019, 7, 251. | | 26 |
| 27 | Regulatory T cells in cancer immunosuppression â€” implications for anticancer therapy. Nature Reviews Clinical Oncology, 2019, 16, 356-371. | 27.6 | 872 |
| 28 | Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. Clinical Cancer Research, 2019, 25, 4808-4819. | 7.0 | 66 |
| 29 | PD-1<sup>+</sup>regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9999-10008. | 7.1 | 655 |
| 30 | Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Antiâ€“PD-1 Therapy. Journal of Investigative Dermatology, 2019, 139, 1490-1496. | 0.7 | 15 |
| 31 | Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids. Journal of Experimental Medicine, 2019, 216, 2701-2713. | 8.5 | 82 |
| 32 | Mutational activation of the epidermal growth factor receptor downâ€regulates major histocompatibility complex class I expression via the extracellular signalâ€regulated kinase in nonâ€“small cell lung cancer. Cancer Science, 2019, 110, 52-60. | 3.9 | 31 |
| 33 | Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).. Journal of Clinical Oncology, 2019, 37, 2522-2522. | 1.6 | 55 |
| 34 | Voltage: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer.. Journal of Clinical Oncology, 2019, 37, 3606-3606. | 1.6 | 12 |
| 35 | TENERGY: Multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with locally advanced esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2019, 37, TPS4141-TPS4141. | 1.6 | 2 |
| 36 | Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment. , 2018, 6, 106. | | 138 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer. Molecular Cancer Therapeutics, 2017, 16, 357-364. | 4.1 | 65 |
| 38 | Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation. Current Topics in Microbiology and Immunology, 2017, 410, 3-27. | 1.1 | 48 |
| 39 | Suppression from beyond the grave. Nature Immunology, 2017, 18, 1285-1286. | 14.5 | 10 |
| 40 | Regulatory-T cells (Tregs) in tumor infiltrating lymphocytes (TILs) from patients with advanced gastric cancer (AGC) after chemotherapy containing ramucirumab.. Journal of Clinical Oncology, 2017, 35, e15570-e15570. | 1.6 | 0 |
| 41 | Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation. Lung Cancer, 2016, 101, 11-15. | 2.0 | 9 |